949922-27-4Relevant articles and documents
GPR103 antagonists demonstrating anorexigenic activity in vivo: Design and development of pyrrolo[2,3- c ]pyridines that mimic the c-terminal arg-phe motif of QRFP26
Georgsson, Jennie,Bergstr?m, Fredrik,Nordqvist, Anneli,Watson, Martin J.,Blundell, Charles D.,Johansson, Magnus J.,Petersson, Annika U.,Yuan, Zhong-Qing,Zhou, Yiqun,Kristensson, Lisbeth,Kakol-Palm, Dorota,Tyrchan, Christian,Wellner, Eric,Bauer, Udo,Brodin, Peter,Svensson Henriksson, Anette
, p. 5935 - 5948 (2014)
GPR103, a G-protein coupled receptor, has been reported to have orexigenic properties through activation by the endogenous neuropeptide ligands QRFP26 and QRFP43. Recognizing that central administration of QRFP26 and QRFP43 increases high fat food intake in rats, we decided to investigate if antagonists of GPR103 could play a role in managing feeding behaviors. Here we present the development of a new series of pyrrolo[2,3-c]pyridines as GPR103 small molecule antagonists with GPR103 affinity, drug metabolism and pharmacokinetics and safety parameters suitable for drug development. In a preclinical obesity model measuring food intake, the anorexigenic effect of a pyrrolo[2,3-c]pyridine GPR103 antagonist was demonstrated. In addition, the dynamic 3D solution structure of the C-terminal heptapeptide of the endogenous agonist QRFP26 (20-26) was determined using NMR. The synthetic pyrrolo[2,3-c] pyridine antagonists were compared to this experimental structure, which displayed a possible overlay of pharmacophore features supportive for further design of GPR103 antagonists.
PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES
-
, (2008/06/13)
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are parti